537 related articles for article (PubMed ID: 21664068)
1. Comparison of prophylactic naftopidil, tamsulosin, and silodosin for 125I brachytherapy-induced lower urinary tract symptoms in patients with prostate cancer: randomized controlled trial.
Tsumura H; Satoh T; Ishiyama H; Tabata K; Kotani S; Minamida S; Kimura M; Fujita T; Matsumoto K; Kitano M; Hayakawa K; Baba S
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e385-92. PubMed ID: 21664068
[TBL] [Abstract][Full Text] [Related]
2. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
[TBL] [Abstract][Full Text] [Related]
3. Use of alpha-1 adrenoceptor antagonists in patients who underwent low-dose-rate brachytherapy for prostate cancer - a randomized controlled trial of silodosin versus naftopidil.
Tanaka N; Torimoto K; Asakawa I; Miyake M; Anai S; Hirayama A; Hasegawa M; Konishi N; Fujimoto K
Radiat Oncol; 2014 Dec; 9():302. PubMed ID: 25544509
[TBL] [Abstract][Full Text] [Related]
4. Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial.
Gotoh M; Kamihira O; Kinukawa T; Ono Y; Ohshima S; Origasa H;
BJU Int; 2005 Sep; 96(4):581-6. PubMed ID: 16104914
[TBL] [Abstract][Full Text] [Related]
5. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe.
Chapple CR; Montorsi F; Tammela TL; Wirth M; Koldewijn E; Fernández Fernández E;
Eur Urol; 2011 Mar; 59(3):342-52. PubMed ID: 21109344
[TBL] [Abstract][Full Text] [Related]
6. Non-inferiority of silodosin to tamsulosin in treating patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).
Yu HJ; Lin AT; Yang SS; Tsui KH; Wu HC; Cheng CL; Cheng HL; Wu TT; Chiang PH
BJU Int; 2011 Dec; 108(11):1843-8. PubMed ID: 21592295
[TBL] [Abstract][Full Text] [Related]
7. A meta-analysis of efficacy and safety of the new α1A-adrenoceptor-selective antagonist silodosin for treating lower urinary tract symptoms associated with BPH.
Wu YJ; Dong Q; Liu LR; Wei Q
Prostate Cancer Prostatic Dis; 2013 Mar; 16(1):79-84. PubMed ID: 22986578
[TBL] [Abstract][Full Text] [Related]
8. Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men.
Kawabe K; Yoshida M; Homma Y;
BJU Int; 2006 Nov; 98(5):1019-24. PubMed ID: 16945121
[TBL] [Abstract][Full Text] [Related]
9. Does combination therapy with tamsulosin and trospium chloride improve lower urinary tract symptoms after SEEDS brachytherapy for prostate cancer compared with tamsulosin alone? : A prospective, randomized, controlled trial.
Yan M; Xue P; Wang K; Gao G; Zhang W; Sun F
Strahlenther Onkol; 2017 Sep; 193(9):714-721. PubMed ID: 28612083
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of silodosin in comparison to tamsulosin in benign prostatic hyperplasia: a randomized controlled trial.
Pande S; Hazra A; Kundu AK
Indian J Pharmacol; 2014; 46(6):601-7. PubMed ID: 25538330
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Silodosin and Naftopidil for Efficacy in the Treatment of Benign Prostatic Enlargement Complicated by Overactive Bladder: A Randomized, Prospective Study (SNIPER Study).
Matsukawa Y; Funahashi Y; Takai S; Majima T; Ogawa T; Narita H; Kato M; Gotoh M
J Urol; 2017 Feb; 197(2):452-458. PubMed ID: 27615436
[TBL] [Abstract][Full Text] [Related]
12. Prophylactic tamsulosin (Flomax) in patients undergoing prostate 125I brachytherapy for prostate carcinoma: final report of a double-blind placebo-controlled randomized study.
Elshaikh MA; Ulchaker JC; Reddy CA; Angermeier KW; Klein EA; Chehade N; Altman A; Ciezki JP
Int J Radiat Oncol Biol Phys; 2005 May; 62(1):164-9. PubMed ID: 15850917
[TBL] [Abstract][Full Text] [Related]
13. Silodosin versus naftopidil in Japanese patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized multicenter study.
Shirakawa T; Haraguchi T; Shigemura K; Morishita S; Minayoshi K; Miyazaki J; Yamada Y; Miyake H; Tanaka K; Fujisawa M
Int J Urol; 2013 Sep; 20(9):903-10. PubMed ID: 23252453
[TBL] [Abstract][Full Text] [Related]
14. Silodosin as second-line α-blocker monotherapy in patients with benign prostatic hyperplasia: A prospective observational study.
Ichihara K; Masumori N; Iwasawa A; Taguchi K; Yamaguchi Y; Nishimura M; Sasamura H; Suzuki N; Haga K; Miyao N; Hirose T
Int J Urol; 2018 Oct; 25(10):849-854. PubMed ID: 30066966
[TBL] [Abstract][Full Text] [Related]
15. Randomized Crossover Comparison of the Short-Term Efficacy and Safety of Single Half-Dose Silodosin and Tamsulosin Hydrochoride in Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.
Takeshita H; Moriyama S; Arai Y; Washino S; Saito K; Chiba K; Horiuchi S; Noro A
Low Urin Tract Symptoms; 2016 Jan; 8(1):38-43. PubMed ID: 26789541
[TBL] [Abstract][Full Text] [Related]
16. New alpha blockers to treat male lower urinary tract symptoms.
Hwang EC; Gandhi S; Jung JH
Curr Opin Urol; 2018 May; 28(3):273-276. PubMed ID: 29613909
[TBL] [Abstract][Full Text] [Related]
17. Post-Marketing Surveillance of Silodosin in Patients with Benign Prostatic Hyperplasia and Poor Response to Existing Alpha-1 Blockers: The SPLASH Study.
Takahashi H; Kubono S; Taneyama T; Kuramoto K; Mizutani H; Tanaka N; Yoshida M
Drugs R D; 2019 Mar; 19(1):47-55. PubMed ID: 30607819
[TBL] [Abstract][Full Text] [Related]
18. Ejaculatory disorders caused by alpha-1 blockers for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: comparison of naftopidil and tamsulosin in a randomized multicenter study.
Masumori N; Tsukamoto T; Iwasawa A; Furuya R; Sonoda T; Mori M;
Urol Int; 2009; 83(1):49-54. PubMed ID: 19641359
[TBL] [Abstract][Full Text] [Related]
19. Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia.
Garimella PS; Fink HA; Macdonald R; Wilt TJ
Cochrane Database Syst Rev; 2009 Oct; (4):CD007360. PubMed ID: 19821408
[TBL] [Abstract][Full Text] [Related]
20. [Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe].
Chapple ChR; Montorsi F; Tammela TL; Wirth M; Koldewijn E; Fernandez Fernandez E
Urologiia; 2012; (5):38-42, 44-5. PubMed ID: 23342615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
